Ahead of print
Research paper
Published online: 2024-03-05

open access

Page views 101
Article views/downloads 22
Get Citation

Connect on Social Media

Connect on Social Media

The prevalence and impact of overweight and hypertension among patients with pancreatic cancer

Marta Fudalej12, Izabella Cichowska3, Anna Badowska-Kozakiewicz1, Andrzej Deptała12

Abstract

Introduction. Pancreatic cancer (PC) remains one of the most deadly malignancies with rising incidence. As therapeutical options seem unsatisfactory, great effort should be put into identifying and reducing risk factors as well as distinguishing possible factors influencing patient outcomes. The study aimed to describe the prevalence of overweight and hypertension among PC patients, analyse the possible association between overweight, hypertension and clinicopathological factors and distinguish variables influencing survival. 

Material and methods. A retrospective analysis of medical records was performed. The study was designed in two branches: (1) the comparison of patients with hypertension (HTN group) and without; (2) the comparison of patients with BMI ≥ 25 and patients with BMI < 25. Statistical analysis with the usage of appropriate tests was conducted. 

Results. No differences in survival between studied groups in the two branches were determined, even after subdividing into adjuvant and palliative types of treatment. Patients with HTN were more likely to be older, have diabetes and be diagnosed without distant metastases. BMI, ACEIs/ARBs use, diabetes, CRP/lymphocyte ratio (CLR) and AJCC IIb stage influenced survival. Patients with overweight/obesity were more likely to have an autoimmune disease, metastases in ≥ 4 lymph nodes (N2), tumour size between 2 and 4 cm (T2) and experience neutropenia as side effect of palliative chemotherapy. Higher BMI and CRP level influenced survival. 

Conclusions. The exact effect of ACEIs/ARBs on cancerogenesis should be further studied. CLR appears to be a feasible marker for prognosis in PC.

Article available in PDF format

View PDF Download PDF file

References

  1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249.
  2. Arnold M, Abnet CC, Neale RE, et al. Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology. 2020; 159(1): 335–349.e15.
  3. Olakowski M, Bułdak Ł. Modifiable and Non-Modifiable Risk Factors for the Development of Non-Hereditary Pancreatic Cancer. Medicina (Kaunas). 2022; 58(8).
  4. Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021; 18(7): 493–502.
  5. Fudalej M, Kwaśniewska D, Nurzyński P, et al. New Treatment Options in Metastatic Pancreatic Cancer. Cancers (Basel). 2023; 15(8).
  6. McGuigan A, Kelly P, Turkington RC, et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018; 24(43): 4846–4861.
  7. Chung V, Sun V, Ruel N, et al. Improving Palliative Care and Quality of Life in Pancreatic Cancer Patients. J Palliat Med. 2022; 25(5): 720–727.
  8. Park SK, Oh CM, Kim MH, et al. Metabolic syndrome, metabolic components, and their relation to the risk of pancreatic cancer. Cancer. 2020; 126(9): 1979–1986.
  9. Xia B, He Q, Pan Y, et al. Metabolic syndrome and risk of pancreatic cancer: A population-based prospective cohort study. Int J Cancer. 2020; 147(12): 3384–3393.
  10. Higuera O, Ghanem I, Nasimi R, et al. Management of pancreatic cancer in the elderly. World J Gastroenterol. 2016; 22(2): 764–775.
  11. Saad MA, Cardoso GP, Martins Wd, et al. Prevalence of metabolic syndrome in elderly and agreement among four diagnostic criteria. Arq Bras Cardiol. 2014; 102(3): 263–269.
  12. Fan Z, Luo G, Gong Y, et al. Prognostic Value of the C-Reactive Protein/Lymphocyte Ratio in Pancreatic Cancer. Ann Surg Oncol. 2020; 27(10): 4017–4025.
  13. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020; 16(4): 223–237.
  14. Zanini S, Renzi S, Limongi AR, et al. A review of lifestyle and environment risk factors for pancreatic cancer. Eur J Cancer. 2021; 145: 53–70.
  15. Badowska-Kozakiewicz A, Fudalej M, Kwaśniewska D, et al. Diabetes Mellitus and Pancreatic Ductal Adenocarcinoma-Prevalence, Clinicopathological Variables, and Clinical Outcomes. Cancers (Basel). 2022; 14(12).
  16. Lee W, Yoon YS, Han HS, et al. Prognostic relevance of preoperative diabetes mellitus and the degree of hyperglycemia on the outcomes of resected pancreatic ductal adenocarcinoma. J Surg Oncol. 2016; 113(2): 203–208.
  17. Chen Ke, Qian W, Jiang Z, et al. Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Mol Cancer. 2017; 16(1): 131.
  18. Gu Y, Zhang B, Gu G, et al. Metformin Increases the Chemosensitivity of Pancreatic Cancer Cells to Gemcitabine by Reversing EMT Through Regulation DNA Methylation of miR-663. Onco Targets Ther. 2020; 13: 10417–10429.
  19. Flack JM, Adekola B. Blood pressure and the new ACC/AHA hypertension guidelines. Trends Cardiovasc Med. 2020; 30(3): 160–164.
  20. Nakai Y, Isayama H, Ijichi H, et al. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer. 2010; 103(11): 1644–1648.
  21. Keith SW, Maio V, Arafat HA, et al. Angiotensin blockade therapy and survival in pancreatic cancer: a population study. BMC Cancer. 2022; 22(1): 150.
  22. Khoshghamat N, Jafari N, Toloue-Pouya V, et al. The therapeutic potential of renin-angiotensin system inhibitors in the treatment of pancreatic cancer. Life Sci. 2021; 270: 119118.
  23. Mandilaras V, Bouganim N, Yin H, et al. The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer. Br J Cancer. 2017; 116(1): 103–108.
  24. Messerli F, Bangalore S, Bavishi C, et al. Angiotensin-Converting Enzyme Inhibitors in Hypertension. Journal of the American College of Cardiology. 2018; 71(13): 1474–1482.
  25. Yamana Y, Fujihara S, Kobara H, et al. MicroRNA profiles following telmisartan treatment in pancreatic ductal adenocarcinoma cells. J Cancer Res Ther. 2022; 18(Supplement): S305–S312.
  26. Zhou T, Xie Y, Hou X, et al. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. J Exp Clin Cancer Res. 2023; 42(1): 111.
  27. Jiang W, He Ru, Lu Y, et al. The relationships between antihypertensive medications and the overall survival of patients with pancreatic cancer: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2022; 16(6): 547–553.
  28. Yang A, Zylberberg HM, Rustgi SD, et al. Beta-blockers have no impact on survival in pancreatic ductal adenocarcinoma prior to cancer diagnosis. Sci Rep. 2021; 11(1): 1038.
  29. Udumyan R, Montgomery S, Fang F, et al. Beta-Blocker Drug Use and Survival among Patients with Pancreatic Adenocarcinoma. Cancer Res. 2017; 77(13): 3700–3707.
  30. Tingle SJ, Severs GR, Moir JAG, et al. Calcium channel blockers in pancreatic cancer: increased overall survival in a retrospective cohort study. Anticancer Drugs. 2020; 31(7): 737–741.
  31. Principe DR, Aissa AF, Kumar S, et al. Calcium channel blockers potentiate gemcitabine chemotherapy  in pancreatic cancer. Proc Natl Acad Sci U S A. 2022; 119(18): e2200143119.
  32. Neumann CCM, Schneider F, Hilfenhaus G, et al. Impact of Smoking, Body Weight, Diabetes, Hypertension and Kidney Dysfunction on Survival in Pancreatic Cancer Patients-A Single Center Analysis of 2323 Patients within the Last Decade. J Clin Med. 2023; 12(11).
  33. Iede K, Yamada T, Ueda M, et al. Do antihypertensive drugs really have antitumor effects? Baseline differences in hypertensive and non-hypertensive patients with advanced pancreatic cancer. Medicine (Baltimore). 2022; 101(29): e29532.
  34. Cillóniz C, Torres A, Garcia-Vidal C, et al. COVID19-Researchers. The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia. Arch Bronconeumol. 2021; 57: 79–82.
  35. Yuan C, Morales-Oyarvide V, Khalaf N, et al. Prediagnostic Inflammation and Pancreatic Cancer Survival. J Natl Cancer Inst. 2021; 113(9): 1186–1193.
  36. Li Z, Jin L, Xia Lu, et al. Body mass index, C-reactive protein, and pancreatic cancer: A Mendelian randomization analysis to investigate causal pathways. Front Oncol. 2023; 13: 1042567.
  37. Shen F, Liu C, Zhang W, et al. Serum levels of IL-6 and CRP can predict the efficacy of mFOLFIRINOX in patients with advanced pancreatic cancer. Front Oncol. 2022; 12: 964115.
  38. Eibl G, Cruz-Monserrate Z, Korc M, et al. Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer. J Acad Nutr Diet. 2018; 118(4): 555–567.
  39. Carreras-Torres R, Johansson M, Gaborieau V, et al. The Role of Obesity, Type 2 Diabetes, and Metabolic Factors in Pancreatic Cancer: A Mendelian Randomization Study. J Natl Cancer Inst. 2017; 109(9).
  40. Hou YC, Chen CY, Huang CJ, et al. The Differential Clinical Impacts of Cachexia and Sarcopenia on the Prognosis of Advanced Pancreatic Cancer. Cancers (Basel). 2022; 14(13).
  41. Lee DH, Giovannucci EL. The Obesity Paradox in Cancer: Epidemiologic Insights and Perspectives. Curr Nutr Rep. 2019; 8(3): 175–181.
  42. Trestini I, Carbognin L, Bonaiuto C, et al. The obesity paradox in cancer: clinical insights and perspectives. Eat Weight Disord. 2018; 23(2): 185–193.
  43. Lennon H, Sperrin M, Badrick E, et al. The Obesity Paradox in Cancer: a Review. Curr Oncol Rep. 2016; 18(9): 56.
  44. Cespedes Feliciano EM, Kroenke CH, Caan BJ. The Obesity Paradox in Cancer: How Important Is Muscle? Annu Rev Nutr. 2018; 38: 357–379.
  45. Arends J, Strasser F, Gonella S, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines. ESMO Open. 2021; 6(3): 100092.
  46. Poulia KA, Sarantis P, Antoniadou D, et al. Pancreatic Cancer and Cachexia-Metabolic Mechanisms and Novel Insights. Nutrients. 2020; 12(6).
  47. Fearon KCH, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012; 16(2): 153–166.